MA52014A - Anticorps anti-klk5 et méthodes d'utilisation - Google Patents

Anticorps anti-klk5 et méthodes d'utilisation

Info

Publication number
MA52014A
MA52014A MA052014A MA52014A MA52014A MA 52014 A MA52014 A MA 52014A MA 052014 A MA052014 A MA 052014A MA 52014 A MA52014 A MA 52014A MA 52014 A MA52014 A MA 52014A
Authority
MA
Morocco
Prior art keywords
methods
klk5 antibodies
klk5
antibodies
Prior art date
Application number
MA052014A
Other languages
English (en)
Inventor
Cecilia P C Chiu
Hilda Y Hernandez-Barry
David B Iaea
Moulay Hicham Alaoui Ismaili
James T Koerber
wei yu Lin
Kelly Loyet
Jawahar Sudhamsu
Yonglian Sun
Benjamin T Walters
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52014A publication Critical patent/MA52014A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052014A 2018-03-14 2019-03-14 Anticorps anti-klk5 et méthodes d'utilisation MA52014A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862643034P 2018-03-14 2018-03-14

Publications (1)

Publication Number Publication Date
MA52014A true MA52014A (fr) 2021-01-20

Family

ID=66175479

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052014A MA52014A (fr) 2018-03-14 2019-03-14 Anticorps anti-klk5 et méthodes d'utilisation

Country Status (20)

Country Link
US (3) US20200040103A1 (fr)
EP (1) EP3765606A1 (fr)
JP (3) JP7422671B2 (fr)
KR (1) KR20200130823A (fr)
CN (1) CN111868241A (fr)
AR (1) AR114281A1 (fr)
AU (1) AU2019235881A1 (fr)
BR (1) BR112020018571A2 (fr)
CA (1) CA3091836A1 (fr)
CL (1) CL2020002333A1 (fr)
CR (1) CR20200404A (fr)
IL (1) IL277212A (fr)
MA (1) MA52014A (fr)
MX (1) MX2020009465A (fr)
PE (1) PE20210629A1 (fr)
PH (1) PH12020551336A1 (fr)
RU (1) RU2020133229A (fr)
SG (1) SG11202008049XA (fr)
TW (1) TW201946935A (fr)
WO (1) WO2019178316A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US12312414B2 (en) * 2019-09-18 2025-05-27 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
GB202001447D0 (en) * 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
US20240052031A1 (en) * 2020-12-18 2024-02-15 Bioardis, Llc Cea6 binding molecules and uses thereof
CN117062839A (zh) * 2021-03-12 2023-11-14 基因泰克公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
WO2023158431A1 (fr) * 2022-02-18 2023-08-24 Adlai Nortye Usa Inc. Anticorps anti-tnfr2 et son application
WO2024052922A1 (fr) 2022-09-11 2024-03-14 Yeda Research And Development Co. Ltd. Anticorps anti-klk4 et leurs utilisations
WO2024091870A2 (fr) * 2022-10-24 2024-05-02 Phanes Therapeutics, Inc. Anticorps anti-egfrviii et leurs utilisations

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (fr) 1991-09-19 2003-11-11 Paul J. Carter Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
DK72593D0 (da) 1993-06-18 1993-06-18 Symbicom Ab Rekombinant protein
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US7282198B2 (en) 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (fr) 1997-06-24 2011-06-14 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (fr) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
EP1240319A1 (fr) 1999-12-15 2002-09-18 Genentech, Inc. Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU2001235829A1 (en) 2000-03-02 2001-09-12 Isis Innovation Limited Mutations in spink5 responsible for netherton's syndrome and atopic diseases
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
ATE510214T1 (de) 2000-11-30 2011-06-15 Crawford Healthcare Holdings Ltd Krankheitsdiagnose
ATE515940T1 (de) 2001-02-09 2011-07-15 Torbjoern Egelrud Scce transgene mäuse und deren verwendung als modell für menschliche krankheiten
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
EP1502603A4 (fr) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA
CA2481837A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
CA2488441C (fr) 2002-06-03 2015-01-27 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (fr) 2002-12-16 2008-07-16 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20180360981A1 (en) 2003-09-26 2018-12-20 Xencor, Inc. Novel immunoglobulin variants
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
EP3434275A1 (fr) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Méthode de dépistage de cellules cancéreuses basé sur l'utilisation de conjugués d'auristatin avec anticorps
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005075667A1 (fr) 2004-02-03 2005-08-18 Bayer Healthcare Ag Methodes de diagnostic et de traitement de maladies associees a la kallikreine 7 (klk7)
EP1721003A1 (fr) * 2004-02-18 2006-11-15 Bayer HealthCare AG Diagnostic et therapeutique de maladies associees a la kallikreine 5 (klk5)
US20170166655A1 (en) 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
CA2561686C (fr) 2004-03-31 2014-12-02 Genentech, Inc. Anticorps anti-tgf-beta humanises
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
WO2007064919A2 (fr) 2005-12-02 2007-06-07 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
CA2637663C (fr) 2006-01-24 2015-06-02 Brown University Dispositif et procede d'agregation et d'encapsulation cellulaires
CA2651567A1 (fr) 2006-05-09 2007-11-22 Genentech, Inc. Polypeptides de liaison a squelettes optimises
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2109457B1 (fr) 2007-02-12 2016-01-06 CSL Behring GmbH Application thérapeutique d'inhibiteurs de sérine protéase de type kazal
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
AR067336A1 (es) 2007-06-28 2009-10-07 Novartis Ag Moduladores de calicreina 7
MX2010001849A (es) 2007-08-17 2010-03-10 Novartis Ag Depsipeptidos ciclicos.
JP5401459B2 (ja) 2007-08-17 2014-01-29 ノバルティス アーゲー カリクレイン７を阻害するための環状デプシペプチドの使用
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US20110130338A1 (en) 2008-01-21 2011-06-02 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
JP5785493B2 (ja) 2008-09-17 2015-09-30 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法
US20170247470A9 (en) 2008-09-17 2017-08-31 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
KR101834999B1 (ko) 2008-10-14 2018-03-06 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
DE102009010942A1 (de) 2009-02-27 2010-09-02 Universitätsklinikum Schleswig-Holstein Serinprotease-Inhibitoren zur spezifischen Inhibition von Gewebs-Kallikreinen
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
WO2011050270A2 (fr) 2009-10-23 2011-04-28 Tranzyme Pharma, Inc. Inhibiteurs macrocycliques des enzymes de protéase de sérine
WO2011091078A2 (fr) 2010-01-19 2011-07-28 Xencor, Inc. Variants d'anticorps possédant une activité complémentaire accrue
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
PL3053932T3 (pl) 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
WO2012083385A1 (fr) 2010-12-23 2012-06-28 Queensland University Of Technology Inhibiteurs de sérine protéase
WO2012174569A2 (fr) 2011-06-17 2012-12-20 The Board Of Trustees Of The University Of Arkansas Nouveaux marqueurs pour diagnostic précoce du cancer de l'ovaire, surveillance au cours de la thérapie, et nouvelles options thérapeutiques pendant et après la chimiothérapie
CA2898100C (fr) 2013-01-14 2023-10-10 Xencor, Inc. Nouvelles proteines heterodimeres
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
EP3097084B1 (fr) 2014-01-23 2020-09-30 Sixera Pharma AB Nouveaux inhibiteurs de la kallikréine 7
PT3097085T (pt) 2014-01-23 2020-10-08 Sixera Pharma Ab Derivados de benzoxazinona para tratamento de doenças de pele
WO2015114144A1 (fr) 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement du syndrôme de netherton
US10821094B2 (en) 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
CA3059615A1 (fr) * 2017-04-21 2018-10-25 Genentech, Inc. Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI848016B (zh) 2018-11-07 2024-07-11 日商第一三共股份有限公司 抑制ｋｌｋ５之胜肽、其製造及鑑定方法
EP3999530A1 (fr) 2019-07-15 2022-05-25 Ecole Polytechnique Federale De Lausanne (Epfl) Nouveaux inhibiteurs des protéases kallicréines et utilisations associées
US12312414B2 (en) 2019-09-18 2025-05-27 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
IL291398B2 (en) 2019-10-01 2025-05-01 Molecular Skin Therapeutics Inc Benzoxazinone compounds as dual inhibitors of KLK5/7
EP4054713A4 (fr) 2019-11-04 2024-02-07 Azitra, Inc. Compositions et méthodes de traitement ou de prévention de maladies et de troubles cutanés au moyen de lekti
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele

Also Published As

Publication number Publication date
CL2020002333A1 (es) 2021-01-15
CA3091836A1 (fr) 2019-09-19
RU2020133229A3 (fr) 2022-04-14
AU2019235881A1 (en) 2020-09-17
WO2019178316A1 (fr) 2019-09-19
US20200040103A1 (en) 2020-02-06
SG11202008049XA (en) 2020-09-29
PH12020551336A1 (en) 2021-12-13
PE20210629A1 (es) 2021-03-23
US12037412B2 (en) 2024-07-16
BR112020018571A2 (pt) 2020-12-29
US20210301032A1 (en) 2021-09-30
JP2026048647A (ja) 2026-03-17
JP2024054130A (ja) 2024-04-16
CR20200404A (es) 2020-11-12
TW201946935A (zh) 2019-12-16
MX2020009465A (es) 2020-10-22
JP7776544B2 (ja) 2025-11-26
JP2021518105A (ja) 2021-08-02
CN111868241A (zh) 2020-10-30
US20250002609A1 (en) 2025-01-02
JP7422671B2 (ja) 2024-01-26
RU2020133229A (ru) 2022-04-14
IL277212A (en) 2020-10-29
AR114281A1 (es) 2020-08-12
KR20200130823A (ko) 2020-11-20
EP3765606A1 (fr) 2021-01-20

Similar Documents

Publication Publication Date Title
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3383431A4 (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d'utilisation
EP4004051A4 (fr) Anticorps immunomodulateurs et leurs méthodes d'utilisation
EP3893931A4 (fr) Méthodes d'utilisation d'anticorps anti-trem2
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
EP3743109A4 (fr) Anticorps anti-mica/b et leurs méthodes d'utilisation
EP3538153C0 (fr) Anticorps anti-cd46 et méthodes d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3994174A4 (fr) Anticorps anti-fzd monospecifiques et méthodes d'utilisation
MA45602A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation